Related Experiment Video
Updated: May 10, 2026
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
Dabrafenib in the treatment of advanced melanoma
T Medina1, M N Amaria, A Jimeno
1Division of Hematology and Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA.
Abstract:
Advanced melanoma has long been a challenging malignancy to treat due to a relative paucity of efficacious therapeutic options. However, the identification of activating BRAF mutations in approximately 50% of patients with cutaneous melanoma has ushered in the era of targeted therapy for melanoma patients. Similar to the first-in-class selective serine/threonine-protein kinase B-raf inhibitor vemurafenib, dabrafenib is highly efficacious in melanoma patients with BRAF V600E mutations, with response rates of approximately 50% and progression-free survival of 6 months. There is data to suggest that dabrafenib not only shows activity in V600E-mutated melanoma, but also in non-V600E BRAF-mutated disease such as V600K. There is also early data to suggest that dabrafenib is effective in controlling metastases in the brain. Combining dabrafenib with the selective mitogen-activated protein kinase kinase (MEK) inhibitor trametinib has been effective in improving both the progression-free survival and overall survival of melanoma patients over those patients treated with dabrafenib alone. Dabrafenib is still being evaluated in several clinical trials in melanoma as well as a variety of other solid tumors with BRAF mutations. The U.S. Food and Drug Administration has recently approved dabrafenib as a single agent for the treatment of unresectable or metastatic melanoma in adult patients with BRAF V600E mutation.
Insights
Dabrafenib is an effective targeted therapy for advanced melanoma with BRAF V600E mutations. Combination therapy with trametinib further improves patient survival, offering new hope for melanoma treatment.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Advanced melanoma presents treatment challenges due to limited effective options.
- Activating BRAF mutations are found in about 50% of cutaneous melanoma cases.
- BRAF mutations have led to the development of targeted therapies.
Purpose of the Study:
- To evaluate the efficacy of dabrafenib, a BRAF inhibitor, in melanoma treatment.
- To assess the impact of combining dabrafenib with trametinib (a MEK inhibitor).
- To review dabrafenib's activity in various BRAF mutation types and metastatic settings.
Main Methods:
- Clinical evaluation of dabrafenib in patients with BRAF-mutated melanoma.
- Assessment of response rates and progression-free survival.
- Analysis of combination therapy with dabrafenib and trametinib.
Main Results:
- Dabrafenib shows high efficacy in BRAF V600E-mutated melanoma (approx. 50% response rate, 6-month PFS).
- Dabrafenib demonstrates activity in non-V600E BRAF mutations (e.g., V600K) and brain metastases.
- Combination of dabrafenib and trametinib significantly improves progression-free and overall survival compared to dabrafenib alone.
Conclusions:
- Dabrafenib is a key targeted therapy for BRAF V600E-mutated melanoma.
- Combination therapy with dabrafenib and trametinib offers superior survival outcomes.
- Dabrafenib continues to be investigated for melanoma and other BRAF-mutated solid tumors.
